Identifying optimal candidates for liver resection or transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma
| Autor: | Huichen Li, Qingling Fan, Xiangnan Zhang, Weijia Dou, Shoujie Zhao, Xilin Du, Mengmeng Wang, Kai Tan, Lei Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Sorafenib
medicine.medical_specialty Performance status business.industry Proportional hazards model Retrospective cohort study General Medicine medicine.disease Gastroenterology Thrombosis BCLC Stage 03 medical and health sciences 0302 clinical medicine Editorial 030220 oncology & carcinogenesis Hepatocellular carcinoma Internal medicine medicine Original Article 030211 gastroenterology & hepatology In patient business medicine.drug |
| Zdroj: | Ann Transl Med |
| ISSN: | 2305-5839 |
| Popis: | BACKGROUND: Recommended as the first-line treatment for advanced unresectable hepatocellular carcinoma (HCC), sorafenib has been shown to prolong median overall survival (OS) for patients. However, advanced HCC sees high heterogeneity across patient groups. Recently, a growing number of studies have indicated surgical resection and transarterial chemoembolisation (TACE) to perform well in patients with portal vein tumor thrombosis (PVTT). The aim of this study was to compare the outcomes of liver resection and TACE and to identify prognostic factors related to OS for BCLC stage C patients with performance status (PS) 1 who have a single tumor but no vascular invasion or extrahepatic spread. METHODS: A total of 323 consecutive patients in BCLC stage C with PS 1 who had only one tumor and no vascular invasion or extrahepatic spread were enrolled in this retrospective study, regardless of tumor size. Survival analyses were performed using the Kaplan-Meier analysis, and statistical differences between the TACE and sorafenib groups were examined by the log-rank test. Univariate and multivariate Cox regression analyses were performed to investigate the prognostic factors for OS. RESULTS: Based on the Kaplan-Meier curves, patients treated with surgical resection showed a better OS than those who underwent TACE, with OS at 1, 3, and 5 years (85.7%, 48.8%, and 33.3% vs. 66.6%, 21.8%, and 13.4%, respectively; log-rank P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|